ABBVIE

Study on MM treatment decision-making highlights QoL, duration of response, and side effects as top attributes for patients, care partners, and physicians. Differences in preferences and trade-offs underscore the importance of shared decision-making (SDM) to align treatment plans with patient values and improve outcomes.

FDA approves Vyalev, an injectable treatment for advanced Parkinson’s, offering 24-hour symptom control via a small pump. Study results show increased 'on' time by 2.7 hours daily compared to oral meds, with notable side effects including skin reactions and hallucinations.

BOTOX® Cosmetic receives FDA approval for temporary improvement in appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults, expanding its aesthetic indications to include forehead lines, frown lines, crow's feet lines, and now platysma bands.

BOTOX® Cosmetic receives FDA approval for temporary improvement in moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults, becoming the first and only product with four aesthetic indications.

AbbVie's Vyalev, a subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson's, has received FDA approval after a 18-month delay. Vyalev, delivered via a pump, aims to control motor fluctuations better than oral therapies and is expected to be covered by Medicare from the second half of 2025. The drug is already available in the EU under the name Produodopa and has been endorsed for NHS use in England and Wales.

AbbVie's Vyalev (foscarbidopa and foslevodopa) receives FDA approval for treating motor fluctuations in advanced Parkinson’s disease. Vyalev is the first subcutaneous 24-hour levodopa-based infusion therapy. A Phase 3 study showed significant improvements in motor fluctuations, with most adverse reactions being mild to moderate.

REGENXBIO to present ABBV-RGX-314 data for wet AMD at AAO 2024: subretinal delivery results on Oct 19, suprachoroidal delivery for DR on Oct 21, and long-term follow-up for nAMD on Oct 21.

FDA approves AbbVie's Vyalev, a subcutaneous drug for advanced Parkinson's disease, after two prior rejections. Vyalev is the first 24-hour continuous levodopa-based therapy, already launched in 34 countries. AbbVie plans to use data from four clinical studies for tavapadon, acquired through the Cerevel Therapeutics deal, to seek further regulatory approvals.